Free shipping on all orders over $ 500

Uprosertib (GSK2141795)

Cat. No. M6044

All AbMole products are for research use only, cannot be used for human consumption.

Uprosertib (GSK2141795) Structure
Synonym:

GSK795; Uprosertib

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 100 In stock
5mg USD 90 In stock
10mg USD 160 In stock
25mg USD 300 In stock
50mg USD 565 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Uprosertib (GSK2141795) is a potent and selective pan-Akt inhibitor with IC50 values of 180 nM for Akt1, 328 nM for Akt2, and 38 nM for Akt3 respectively.

Chemical Information
Molecular Weight 429.25
Formula C18H16Cl2F2N4O2
CAS Number 1047634-65-0
Solubility (25°C) DMSO 30 mg/mL
Storage -20°C, sealed
Related Akt Products
AT7867

AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase with an IC50 of 17 nM.

GSK690693

GSK690693 is a potent Akt inhibitor (Akt1 IC50 = 2 nM, Akt2 IC50 = 13 nM, Akt3 IC50 = 9 nM) which also inhibited the phosphorylation of the downstream target GSK3b in cells.

Perifosine

Perifosine is an orally active Akt inhibitor, the antiproliferative properties of Perifosine with an IC50 of 0.6–8.9 µM.

MK-2206 2HCl

MK-2206 is a novel allosteric inhibitor of Akt with IC50 values of 8 nM, 12 nM and 65 nM for Akt1, Akt2 and Akt3, respectively.

Ipatasertib

Ipatasertib (GDC-0068, RG7440) is a potent and selective, ATP-competitive Akt inhibitor with IC50 values of 5 to 18 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Uprosertib (GSK2141795), GSK795; Uprosertib supplier, Akt, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.